ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

Biotechnology

Healthcare
$3.69 -3.51%

-$0.35 today

Market cap
$370.95M
Beta
0.83
P/E (TTM)
-4.8
EPS (TTM)
-$1.99
52W Low $6.66High $18.90

Volume 1.70M

Average 1.67M

SPRY Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

ARS Pharmaceuticals, Inc.NASDAQ: SPRY

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses grows, but more slowly than its trailing trend

Q1 FY2026 operating expenses of $76.54M rose 86.2% year over year, behind the +155.2% change in trailing-twelve-month operating expenses. Sequentially, it rose 15.4% from the prior quarter. Over 3 fiscal years it compounded at +131.1% a year.

Context

  • Operating expenses amounted to 288.7% of revenue in FY2025, up 208.3 pp from a year earlier.
  • Operating expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +86.2% toward the trailing-twelve-month pace of +155.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$76.54M+15.4% QoQ
Last fiscal yearDec 2025
$243.3M+239.5% YoY
LTMMar 2026
$278.74M+155.2% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+86.2%——
1 year+239.5%——
3-year CAGR+131.1%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
243.3M USD
Year-over-year change
+239.5%
4-year CAGR
+77.1%

Operating Expenses vs competitors

How SPRY compares with its peers on the latest reported figures

  • SPRY's LTM Mar 2026 operating expenses of $278.74M is the highest of the 4 companies compared; the peer median is $220.98M.
  • Its year-over-year change of +155.2% is the highest of 4, against a peer median of +12.2%.
  • Operating expenses amounts to 281.6% of revenue for SPRY, versus a peer median of 72.2%.
SPRY Competitors Peer median
Operating Expenses for SPRY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SPRYARS Pharmaceuticals, Inc.LTM Mar 2026$278.74M +155.2%+131.1%281.6%
MNKDMannKind CorporationLTM Mar 2026$260.65M +81.1%+32.8%72.2%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$220.98M +9.0%+8.0%70.2%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$87.79M +12.2%+11.3%174.6%
Peer median (excluding SPRY) $220.98M+12.2%+11.3%72.2%

Competitors are the stored peer set for SPRY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.51M1.32M30K89.15M84.28M
Cost of Revenue213K17.12M020.56M20.42M
Gross Profit5.29M(15.8M)30K68.59M63.86M
Gross Margin96.1%-1200.9%100.0%76.9%75.8%
Research & Development20.27M18.38M20.27M19.58M13.18M
Selling, General & Admin4.69M18.66M47.28M0230.12M
Operating Expenses24.75M19.71M67.55M71.68M243.3M
Depreciation & Amortization213K319K73K79K1.37M
EBITDA(19.92M)(34.36M)(54.29M)8.37M(167.41M)
EBITDA Margin-361.9%-2611.2%-180973.3%9.4%-198.6%
Operating Income(19.45M)(35.52M)(67.52M)(3.08M)(179.45M)
Operating Margin-353.3%-2698.8%-225066.7%-3.5%-212.9%
Interest Income800K00010.67M
Interest Expense106K0002.6M
Other Income / Expenses(789K)834K13.16M11.37M8.07M
Income Before Tax(20.24M)(34.68M)(54.37M)8.29M(171.38M)
Pre-Tax Margin-367.7%-2635.4%-181216.7%9.3%-203.3%
Income Tax Expense000288K(80K)
Net Income(20.24M)(34.68M)(54.37M)8M(171.3M)
Net Margin-367.7%-2635.4%-181216.7%9.0%-203.3%
EPS (Basic)(0.70)(0.87)(0.57)0.08(1.74)
EPS (Diluted)(0.70)(0.87)(0.57)0.08(1.74)
Weighted Avg Shares28.87M39.96M95.22M96.94M98.57M
Weighted Avg Shares (Diluted)28.87M39.96M95.22M102.39M98.57M

ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

Intrinsic Alpha fair value

Locked

Current Price

$3.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.